Implementation of New Models of Ovarian Carcinoma Resistant to Therapy

Sponsor
Mario Negri Institute for Pharmacological Research
Study ID
NCT07757711
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Platinum drugs and PARPi — OTHER
    Patients with ovarian carcinoma resistant to platinum drugs and PARPi undergoing paracentasis and/or surgical with left-over tumor material.

Study Details

The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi). These models are essential for testing new drugs or drug combinations in preclinical settings that closely mimic real clinical conditions. These models will also help to identify predictive biomarkers of treatment response and to better understand the biological mechanisms behind therapy resistance.

Key Dates

First listed
Aug 11, 2026
Start date
Aug 1, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2036
Completion
Aug 31, 2036

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Patients with ovarian carcinoma
    Patients with ovarian carcinoma resistant to platinum drugs and PARPi

Primary Outcome Measure

To obtain new in vivo experimental models of ovarian carcinomas [ Time Frame: 10 years ]

Central Contacts

Find similar trials

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies